The pharmaceutical world is witnessing a major shift in diabetes treatment with the introduction of GLP-1 skin applications. These systems offer a potentially more user-friendly alternative to subcutaneous administrations of GLP-1 drugs, lessening the requirement of daily needle sticks. The innovation releases the drug directly through the epidermi